RPG Life Sciences · NSE: RPGLIFE · BSE: 532983
Q1 FY26 results · Apr–Jun 2025
RPG Life Sciences reported revenue from operations of ₹168.92 crore (up 2.1% from Q1 FY25) and net profit of ₹26.29 crore (down 1.8% from Q1 FY25) for Q1 FY26 (Apr–Jun 2025), on a standalone basis.
| Item | Q1 FY26 | Q1 FY25 | YoY | Q4 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 168.92 | 165.42 | +2.1% | 143.09 | +18.1% |
| Other income | 5.23 | 2.37 | +120.7% | 5.06 | +3.4% |
| Total income | 174.15 | 167.79 | +3.8% | 148.15 | +17.5% |
| Profit before tax | 35.43 | 36.00 | −1.6% | 134.90 | −73.7% |
| Net profit for the period | 26.29 | 26.76 | −1.8% | 117.35 | −77.6% |
| EPS, basic (₹) | 15.90 | 16.18 | −1.7% | 70.96 | −77.6% |
| Net margin (%) | 15.6 | 16.2 | 82.0 |
Standalone
- Filed with BSE
- 25 Jul 2025, 20:19 IST
- Board meeting
- 25 Jul 2025
- Period
- 01 Apr 2025 to 30 Jun 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE